Nathan Ihle
Principle Scientist
Pfizer
New Zealand
Biography
Dr. Ihle received his BS in Environmental Biology at the University of Arizona in 2001. Prior to joining Pfizer, he began working in the laboratory of Garth Powis characterizing PI3K inhibitors derived from the natural product Wortmannin. In 2005, the lab moved to MD Anderson in Houston, Texas where Dr. Ihle became a program coordinator for an optimized PI3K inhibitor, leading studies outlining how to mitigate the on-target hyperglycemia seen with PI3K inhibition and describing the interplay between activating KRas and PI3K mutations in determining the response of cancer cells. In 2008, this inhibitor moved to clinical trials and he began working towards his PhD, becoming a full time student in 2010.
Research Interest
Oncology
